Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Calendar quarter Q2 2026Earnings call Jul 23, 2026 · most recent call
EW’s newest analyzed quarter is part of Tellvest Pro: its score, breakdown, narrative and analyst Q&A. Every prior quarter is free.
Sources. Scores: Edwards Lifesciences’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: EW daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
All prior quarters are free. How to browse earnings-call scores without Pro. How to read a company earnings-call score.
The breakdown for this quarter is part of Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $1.39B | +9.4% | $0.65 | +6.6% | 78.9% | 22.6% | 27.8% | $-177M |
| FY2025 Q1 | $1.41B | +6.2% | $0.61 | +5.2% | 78.7% | 27.9% | 25.3% | $224M |
| FY2025 Q2 | $1.53B | +10.6% | $0.56 | -8.2% | 77.6% | 28.1% | 21.5% | $241M |
| FY2025 Q3 | $1.55B | +14.7% | $0.50 | -90.3% | 77.9% | 27.4% | 18.7% | $516M |
| FY2025 Q4 | $1.57B | +13.3% | $0.16 | -75.4% | 78.3% | 23.6% | 5.8% | $354M |
| FY2026 Q1 | $1.65B | +16.7% | $0.66 | +8.2% | 78.2% | 31.2% | 23.1% | $-21M |
| FY2026 Q2Selected | $1.74B | +13.6% | $0.42 | -25.0% | 77.6% | 29.8% | 13.9% | — |
Management-stated figures from EW’s newest call are part of Tellvest Pro.
No 8-K events recorded since this call day.